|
1）Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004; 24: 1454-9
|
|
|
|
2）Costet P, Hoffmann MM, Cariou B, et al. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis. 2010; 212: 246-51
|
|
|
|
|
|
3）Vergès B, Duvillard L, Brindisi MC, et al. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes. Atherosclerosis. 2011; 219: 342-8
|
|
|
|
|
|
4）Bjermo H, Iggman D, Kullberg J, et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr. 2012; 95: 1003-12
|
|
|
|
|
|
5）Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention study. Circulation. 2001; 103: 357-62
|
|
|
|
|
|
6）Sever PS, Dahlöf B, Poulter NR, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361: 1149-58
|
|
|
|
|
|
7）Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003; 361: 2005-16
|
|
|
|
|
|
8）Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359: 2195-207
|
|
|
|
|
|
9）Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012; 380: 565-71
|
|
|
|
|
|
10）Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: A meta-analysis. Diabetes Care. 2009; 32: 1924-9
|
|
|
|
|
|
11）Sattar N, Preiss D, Murray HM, et al. A meta-analysi: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010; 375: 735-42
|
|
|
|
|
|
12）Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008; 371: 1927-35
|
|
|
|
|
|
13）LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352: 1425-35
|
|
|
|
|
|
14）Pedersen TR, Faergeman O, Kastelein JJ. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA. 2005; 294: 2437-45
|
|
|
|
|
|
15）Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin. Results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011; 57: 1535-45
|
|
|
|
|
|
16）Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol. 2013; 61: 148-52
|
|
|
|
|
|
17）Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011; 305: 2556-64
|
|
|
|
|
|
18）Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Womenʼs Health Initiative. Arch Intern Med. 2012; 172: 144-52
|
|
|
|
|
|
19）Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013; 346: f2610
|
|
|
|
|
|
20）Odawara M, Yamazaki T, Kishimoto J, et al. for the J-PREDICT study investigators. Effect of pitavastatin on the incidence of diabetes in Japanese individuals with impaired glucose tolerance. Diabetologia. 2013; 56: s59
|
|
|
|
|